{
    "clinical_study": {
        "@rank": "137799", 
        "acronym": "NSCLC", 
        "arm_group": [
            {
                "arm_group_label": "Selumetinib 75 mg twice daily +Docetaxel 75 mg/m2", 
                "arm_group_type": "Experimental", 
                "description": "Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle."
            }, 
            {
                "arm_group_label": "Selumetinib 75 mg twice daily + Docetaxel 60 mg/m2", 
                "arm_group_type": "Experimental", 
                "description": "Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 60 mg/m2 intravenously administered on day 1 of each 21 day cycle."
            }, 
            {
                "arm_group_label": "Placebo twice daily + Docetaxel 75 mg/m2", 
                "arm_group_type": "Experimental", 
                "description": "Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to treat patients with locally advanced or metastatic NSCLC\n      with a combination therapy of selumetinib and two different doses of docetaxel 75mg/m2 or 60\n      mg/m2 vs placebo and compare how well each dose affects how their cancer responds. It will\n      also help us to understand the tolerability profile of the different dosing regimens in\n      these patients."
        }, 
        "brief_title": "Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and\n      Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel,\n      Compared with Placebo in Combination with Docetaxel, in Patients receiving second line\n      treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provision of signed, written and dated informed consent prior to any study specific\n             procedures\n\n          -  Male or female, aged 18 years or older\n\n          -  Histological or cytological confirmation of locally advanced or metastatic NSCLC\n             (IIIB-IV)\n\n          -  Prospective confirmation of KRAS mutation negative status as determined using the\n             cobas\u00ae KRAS Mutation Test (Roche Molecular Systems) via an AZ approved laboratory\n\n          -  Failure of 1st line anti-cancer therapy due to radiological documentation of disease\n             progression in advanced disease or subsequent relapse of disease following 1st line\n             therapy\n\n        Exclusion Criteria:\n\n          -  Mixed small cell and non-small cell lung cancer histology\n\n          -  Received >1 prior anti-cancer drug regimen for advanced or metastatic NSCLC. Patients\n             who develop disease progression while on switch maintenance therapy (maintenance\n             using an agent not in the first-line regimen) will not be eligible.\n\n          -  Other concomitant anti-cancer therapy agents except steroids\n\n          -  Prior treatment with a MEK (Mitogen-Activated Protein Kinase) inhibitor or any\n             docetaxel-containing regimen (prior treatment with paclitaxel is acceptable)\n\n          -  The last radiation therapy within 4 weeks prior to starting study treatment, or\n             limited field of radiation for palliation within 7 days of the first dose of study\n             treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "265", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01750281", 
            "org_study_id": "D1532C00064", 
            "secondary_id": "EudraCT number: 2012-003622-25"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Selumetinib 75 mg twice daily +Docetaxel 75 mg/m2", 
                    "Selumetinib 75 mg twice daily + Docetaxel 60 mg/m2"
                ], 
                "description": "Three selumetinib capsules (Hyd-Sulfate) 25 mg will be administered orally, twice daily, (75 mg dose bd) on an uninterrupted schedule.", 
                "intervention_name": "Selumetinib 75 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Selumetinib 75 mg twice daily +Docetaxel 75 mg/m2", 
                    "Placebo twice daily + Docetaxel 75 mg/m2"
                ], 
                "description": "Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.", 
                "intervention_name": "Docetaxel 75 mg/m2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Selumetinib 75 mg twice daily + Docetaxel 60 mg/m2", 
                "description": "Docetaxel 60 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.", 
                "intervention_name": "Docetaxel 60 mg/m2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo twice daily + Docetaxel 75 mg/m2", 
                "description": "Three placebo capsules will be administered orally uninterrupted twice daily.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Docetaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Mitogen-Activated Protein Kinase Kinase inhibitor", 
            "Non Small Cell Lung Cancer", 
            "Metastatic", 
            "Second line treatment for Non Small Cell Lung Cancer"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pembroke Pines", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Metairie", 
                        "country": "United States", 
                        "state": "Louisiana"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mineola", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadlephia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barretos", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S\u00e3o Jos\u00e9 do Rio Preto", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S\u00e3o Paulo", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plovdiv", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Varna", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vratza", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brest Cedex", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clermont Ferrand", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille Cedex", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pierre Benite Cedex", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Esslingen", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gro\u00dfhansdorf", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Karlsruhe", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "L\u00f6wenstein", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moers", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wiesbaden", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "W\u00fcrzburg", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edel\u00e9ny", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gy\u0151r", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kaposv\u00e1r", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miskolc", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ny\u00edregyh\u00e1za", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sz\u00e9kesfeh\u00e9rv\u00e1r", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "T\u00f6r\u00f6kb\u00e1lint", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bergen Op Zoom", 
                        "country": "Netherlands"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Den Bosch", 
                        "country": "Netherlands"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maastricht", 
                        "country": "Netherlands"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Brazil", 
                "Bulgaria", 
                "France", 
                "Germany", 
                "Hungary", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, Compared With Placebo in Combination With Docetaxel, in Patients Receiving Second Line Treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV)", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "AstraZeneca Clinical Study Information", 
            "phone": "800-236-9933"
        }, 
        "overall_official": [
            {
                "affiliation": "AstraZeneca UK, MSD", 
                "last_name": "Ian Smith, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Dana-Farber Cancer Institute, USA", 
                "last_name": "Pasi Janne, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institut de Cancerology Gustave Roussy, France", 
                "last_name": "Jean-Charles Soria, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hungary: National Institute of Pharmacy", 
                "Brazil: National Health Surveillance Agency", 
                "Brazil: National Committee of Ethics in Research", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Progression free survival is defined as the time from randomisation until the date of objective disease progression (RECIST 1.1) or death (by any cause in the absence of progression).", 
            "measure": "Progression-Free Survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "Measured at baseline until the date of first documented objective disease progression, assessed up to 16 months."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01750281"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall Survival is defined as the time from the date of randomisation until death due to any cause.", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Measured at baseline until the date of death due to any cause, assessed up to 16 months."
            }, 
            {
                "description": "ORR is defined as the number (%) of subjects with at least one visit response of complete response (CR) or partial response (PR).", 
                "measure": "Objective Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Measured at baseline until the date of first documented objective disease progression, assessed up to 16 months."
            }, 
            {
                "description": "Duration of response will be defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression.", 
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "Measured at baseline until the date of first documented objective disease progression, assessed up to 16 months."
            }, 
            {
                "description": "Percentage change from baseline in tumour size at week 6 based on RECIST 1.1 target lesion measurement.", 
                "measure": "Change in tumour size at week 6", 
                "safety_issue": "No", 
                "time_frame": "At baseline and at week 6"
            }, 
            {
                "description": "The safety and tolerability profile of Selumetinib in Combination With Docetaxel will be assessed using adverse events, clinical chemistry, haematology and urinalysis, vital signs, ECGs and echocardiograms/MUGA.", 
                "measure": "The safety and tolerability profile of Selumetinib in Combination With Docetaxel", 
                "safety_issue": "Yes", 
                "time_frame": "Measured from baseline until 30 days after the date of discontinuation of the last study treatment, assessed up to 16 months."
            }, 
            {
                "description": "Efficacy will be assessed within KRAS mutation subgroups in terms of PFS, OS, ORR and change in tumour size at week 6.\nKRAS: v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog", 
                "measure": "Correlation of KRAS mutation status with efficacy of treatment", 
                "safety_issue": "No", 
                "time_frame": "Measured from date of randomisation until the date of first documented objective disease progression, assessed up to 16 months."
            }, 
            {
                "description": "The effect of HRQoL will be assessed using the summary items of the LCSS-Lung Cancer Symptom Scale (symptom distress, interference with activity levels and global HRQoL); the average LCSS score (the mean of all 9 items of the LCSS); the scores for each of the 8 health domain scales as well as the 2 summary measures of the SF-36v2 (Short Form Health Survey - 36 Items (Version 2)).", 
                "measure": "The effect on health-related quality of life (HRQoL)", 
                "safety_issue": "No", 
                "time_frame": "Measured from baseline until the date of discontinuation of study treatment, assessed up to 16 months."
            }, 
            {
                "description": "The pharmacokinetics (PK) of selumetinib and N-desmethyl selumetinib when administered in combination with docetaxel measured by derived PK parameters, such as AUC and Cmax.\nAUC: Area under plasma concentration time curve", 
                "measure": "The pharmacokinetics (PK) of selumetinib and N-desmethyl selumetinib measured by AUC, Cmax.", 
                "safety_issue": "No", 
                "time_frame": "PK samples taken on day 22"
            }, 
            {
                "description": "The symptom improvement rate will be defined as the number (%) of patients with two consecutive assessments at least 18 days apart (ie 21 days allowing a visit window of 3 days) which showed a clinically meaningful improvement in symptoms from baseline (defined as a decrease in the ASBI from baseline \u226510). LCSS-Lung Cancer Symptom Scale; ASBI-Average symptom burden index.", 
                "measure": "Symptom improvement rate (using ASBI from LCSS)", 
                "safety_issue": "No", 
                "time_frame": "Measured from date of randomisation until 30 days post treatment discontinuation, assessed up to 16 months."
            }, 
            {
                "description": "Time to symptom progression will be defined as the time from randomization until the date of first clinically meaningful symptom deterioration (defined as an increase in the ASBI from baseline \u226510), or death (by any cause). LCSS-Lung Cancer Symptom Scale; ASBI-Average symptom burden index.", 
                "measure": "Time to symptom progression (using ASBI from LCSS)", 
                "safety_issue": "No", 
                "time_frame": "Measured from date of randomisation until 30 days post treatment discontinuation, assessed up to 16 months."
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}